Skip to main content

Table 2 Gene Mutation Frequencies in Pre-treatment Tissue Biopsies

From: Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer

Gene Subset of Subjects with Pre-Treatment Tissue Biopsies (N = 47)
TP53 20 (42.6)
KRAS 12 (25.5)
KEAP1 9 (19.1)
BRAF 6 (12.8)
STK11 5 (10.6)
ERBB2 5 (10.6)
EGFR 2 (4.2)
  1. Data are n (%)